On July 6, 2023, the Board of Directors of Titan Pharmaceuticals, Inc. held a meeting at which it determined that a majority of the Board is comprised of independent directors in accordance with Nasdaq Listing Rule 5605(b)(1)(A). The Board also determined the composition of the Board committees for the upcoming year. The committees of the Board will be constituted as follows: Audit Committee: David Natan (Chair), Eric Greenberg, Matthew McMurdo, Compensation Committee: Matthew McMurdo (Chair), Peter Chasey, David Natan and Nominating and Governance Committee: Avraham Ben-Tzvi (Chair), Peter Chasey, Eric Greenberg.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.09 USD | +1.72% | -3.14% | -14.06% |
Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
1st Jan change | Capi. | |
---|---|---|
-14.06% | 6.48M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Titan Pharmaceuticals, Inc. Announces Board Changes